GSK Wants Fraud Claims Dismissed In Zofran MDL
GlaxoSmithKline PLC on Thursday told a Massachusetts federal court that it shouldn't have to face fraud claims in multidistrict litigation over an alleged off-label marketing scheme for its anti-nausea drug Zofran,...To view the full article, register now.
Already a subscriber? Click here to view full article